Gliclazide is an oral antidiabetic medication used to treat type 2 diabetes mellitus. It belongs to the class of sulfonylurea drugs, which work by stimulating the pancreas to produce more insulin and increasing the body's sensitivity to insulin. Gliclazide sustained-release tablets, often referred to as extended-release or controlled-release tablets, are a specific formulation of this medication.

The global market for Gliclazide Sustained-release Tablet was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gliclazide Sustained-release Tablet, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Gliclazide Sustained-release Tablet by region & country, by Type, and by Application.

The Gliclazide Sustained-release Tablet market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gliclazide Sustained-release Tablet.

Market Segmentation

Scope of Gliclazide Sustained-release Tablet - Market Report

Report Metric	Details
Report Name	Gliclazide Sustained-release Tablet - Market
CAGR	5%
Segment by Type:	30mg 60mg Other
Segment by Application	Hospital Clinic Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Servier Laboratories, Torrent Pharmaceuticals, Aurobindo Pharma, Teva, Zydus Cadila Healthcare, Sanofi S.A., Mylan Pharmaceuticals, Accord Healthcare, Lukang Jituan Saite Yaoye, Shijiazhuang SIYAO, Yiling Pharmaceutical
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gliclazide Sustained-release Tablet manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of Gliclazide Sustained-release Tablet in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of Gliclazide Sustained-release Tablet in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Gliclazide Sustained-release Tablet - Market report?

Ans: The main players in the Gliclazide Sustained-release Tablet - Market are Servier Laboratories, Torrent Pharmaceuticals, Aurobindo Pharma, Teva, Zydus Cadila Healthcare, Sanofi S.A., Mylan Pharmaceuticals, Accord Healthcare, Lukang Jituan Saite Yaoye, Shijiazhuang SIYAO, Yiling Pharmaceutical

What are the Application segmentation covered in the Gliclazide Sustained-release Tablet - Market report?

Ans: The Applications covered in the Gliclazide Sustained-release Tablet - Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the Gliclazide Sustained-release Tablet - Market report?

Ans: The Types covered in the Gliclazide Sustained-release Tablet - Market report are 30mg, 60mg, Other

1 Market Overview

1.1 Gliclazide Sustained-release Tablet Product Introduction

1.2 Global Gliclazide Sustained-release Tablet Market Size Forecast

1.2.1 Global Gliclazide Sustained-release Tablet Sales Value (2019-2030)

1.2.2 Global Gliclazide Sustained-release Tablet Sales Volume (2019-2030)

1.2.3 Global Gliclazide Sustained-release Tablet Sales Price (2019-2030)

1.3 Gliclazide Sustained-release Tablet Market Trends & Drivers

1.3.1 Gliclazide Sustained-release Tablet Industry Trends

1.3.2 Gliclazide Sustained-release Tablet Market Drivers & Opportunity

1.3.3 Gliclazide Sustained-release Tablet Market Challenges

1.3.4 Gliclazide Sustained-release Tablet Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Gliclazide Sustained-release Tablet Players Revenue Ranking (2023)

2.2 Global Gliclazide Sustained-release Tablet Revenue by Company (2019-2024)

2.3 Global Gliclazide Sustained-release Tablet Players Sales Volume Ranking (2023)

2.4 Global Gliclazide Sustained-release Tablet Sales Volume by Company Players (2019-2024)

2.5 Global Gliclazide Sustained-release Tablet Average Price by Company (2019-2024)

2.6 Key Manufacturers Gliclazide Sustained-release Tablet Manufacturing Base Distribution and Headquarters

2.7 Key Manufacturers Gliclazide Sustained-release Tablet Product Offered

2.8 Key Manufacturers Time to Begin Mass Production of Gliclazide Sustained-release Tablet

2.9 Gliclazide Sustained-release Tablet Market Competitive Analysis

2.9.1 Gliclazide Sustained-release Tablet Market Concentration Rate (2019-2024)

2.9.2 Global 5 and 10 Largest Manufacturers by Gliclazide Sustained-release Tablet Revenue in 2023

2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gliclazide Sustained-release Tablet as of 2023)

2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 30mg

3.1.2 60mg

3.1.3 Other

3.2 Global Gliclazide Sustained-release Tablet Sales Value by Type

3.2.1 Global Gliclazide Sustained-release Tablet Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Gliclazide Sustained-release Tablet Sales Value, by Type (2019-2030)

3.2.3 Global Gliclazide Sustained-release Tablet Sales Value, by Type (%) (2019-2030)

3.3 Global Gliclazide Sustained-release Tablet Sales Volume by Type

3.3.1 Global Gliclazide Sustained-release Tablet Sales Volume by Type (2019 VS 2023 VS 2030)

3.3.2 Global Gliclazide Sustained-release Tablet Sales Volume, by Type (2019-2030)

3.3.3 Global Gliclazide Sustained-release Tablet Sales Volume, by Type (%) (2019-2030)

3.4 Global Gliclazide Sustained-release Tablet Average Price by Type (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Hospital

4.1.2 Clinic

4.1.3 Other

4.2 Global Gliclazide Sustained-release Tablet Sales Value by Application

4.2.1 Global Gliclazide Sustained-release Tablet Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Gliclazide Sustained-release Tablet Sales Value, by Application (2019-2030)

4.2.3 Global Gliclazide Sustained-release Tablet Sales Value, by Application (%) (2019-2030)

4.3 Global Gliclazide Sustained-release Tablet Sales Volume by Application

4.3.1 Global Gliclazide Sustained-release Tablet Sales Volume by Application (2019 VS 2023 VS 2030)

4.3.2 Global Gliclazide Sustained-release Tablet Sales Volume, by Application (2019-2030)

4.3.3 Global Gliclazide Sustained-release Tablet Sales Volume, by Application (%) (2019-2030)

4.4 Global Gliclazide Sustained-release Tablet Average Price by Application (2019-2030)

5 Segmentation by Region

5.1 Global Gliclazide Sustained-release Tablet Sales Value by Region

5.1.1 Global Gliclazide Sustained-release Tablet Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Gliclazide Sustained-release Tablet Sales Value by Region (2019-2024)

5.1.3 Global Gliclazide Sustained-release Tablet Sales Value by Region (2025-2030)

5.1.4 Global Gliclazide Sustained-release Tablet Sales Value by Region (%), (2019-2030)

5.2 Global Gliclazide Sustained-release Tablet Sales Volume by Region

5.2.1 Global Gliclazide Sustained-release Tablet Sales Volume by Region: 2019 VS 2023 VS 2030

5.2.2 Global Gliclazide Sustained-release Tablet Sales Volume by Region (2019-2024)

5.2.3 Global Gliclazide Sustained-release Tablet Sales Volume by Region (2025-2030)

5.2.4 Global Gliclazide Sustained-release Tablet Sales Volume by Region (%), (2019-2030)

5.3 Global Gliclazide Sustained-release Tablet Average Price by Region (2019-2030)

5.4 North America

5.4.1 North America Gliclazide Sustained-release Tablet Sales Value, 2019-2030

5.4.2 North America Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

5.5 Europe

5.5.1 Europe Gliclazide Sustained-release Tablet Sales Value, 2019-2030

5.5.2 Europe Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

5.6 Asia Pacific

5.6.1 Asia Pacific Gliclazide Sustained-release Tablet Sales Value, 2019-2030

5.6.2 Asia Pacific Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

5.7 South America

5.7.1 South America Gliclazide Sustained-release Tablet Sales Value, 2019-2030

5.7.2 South America Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

5.8 Middle East & Africa

5.8.1 Middle East & Africa Gliclazide Sustained-release Tablet Sales Value, 2019-2030

5.8.2 Middle East & Africa Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value

6.2.1 Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.2.2 Key Countries/Regions Gliclazide Sustained-release Tablet Sales Volume, 2019-2030

6.3 United States

6.3.1 United States Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.3.2 United States Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.4.2 Europe Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.5.2 China Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.5.3 China Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.6.2 Japan Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.7.2 South Korea Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.8.2 Southeast Asia Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Gliclazide Sustained-release Tablet Sales Value, 2019-2030

6.9.2 India Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

6.9.3 India Gliclazide Sustained-release Tablet Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Servier Laboratories

7.1.1 Servier Laboratories Company Information

7.1.2 Servier Laboratories Introduction and Business Overview

7.1.3 Servier Laboratories Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.1.4 Servier Laboratories Gliclazide Sustained-release Tablet Product Offerings

7.1.5 Servier Laboratories Recent Development

7.2 Torrent Pharmaceuticals

7.2.1 Torrent Pharmaceuticals Company Information

7.2.2 Torrent Pharmaceuticals Introduction and Business Overview

7.2.3 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.2.4 Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product Offerings

7.2.5 Torrent Pharmaceuticals Recent Development

7.3 Aurobindo Pharma

7.3.1 Aurobindo Pharma Company Information

7.3.2 Aurobindo Pharma Introduction and Business Overview

7.3.3 Aurobindo Pharma Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.3.4 Aurobindo Pharma Gliclazide Sustained-release Tablet Product Offerings

7.3.5 Aurobindo Pharma Recent Development

7.4 Teva

7.4.1 Teva Company Information

7.4.2 Teva Introduction and Business Overview

7.4.3 Teva Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.4.4 Teva Gliclazide Sustained-release Tablet Product Offerings

7.4.5 Teva Recent Development

7.5 Zydus Cadila Healthcare

7.5.1 Zydus Cadila Healthcare Company Information

7.5.2 Zydus Cadila Healthcare Introduction and Business Overview

7.5.3 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.5.4 Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product Offerings

7.5.5 Zydus Cadila Healthcare Recent Development

7.6 Sanofi S.A.

7.6.1 Sanofi S.A. Company Information

7.6.2 Sanofi S.A. Introduction and Business Overview

7.6.3 Sanofi S.A. Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.6.4 Sanofi S.A. Gliclazide Sustained-release Tablet Product Offerings

7.6.5 Sanofi S.A. Recent Development

7.7 Mylan Pharmaceuticals

7.7.1 Mylan Pharmaceuticals Company Information

7.7.2 Mylan Pharmaceuticals Introduction and Business Overview

7.7.3 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.7.4 Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product Offerings

7.7.5 Mylan Pharmaceuticals Recent Development

7.8 Accord Healthcare

7.8.1 Accord Healthcare Company Information

7.8.2 Accord Healthcare Introduction and Business Overview

7.8.3 Accord Healthcare Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.8.4 Accord Healthcare Gliclazide Sustained-release Tablet Product Offerings

7.8.5 Accord Healthcare Recent Development

7.9 Lukang Jituan Saite Yaoye

7.9.1 Lukang Jituan Saite Yaoye Company Information

7.9.2 Lukang Jituan Saite Yaoye Introduction and Business Overview

7.9.3 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.9.4 Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product Offerings

7.9.5 Lukang Jituan Saite Yaoye Recent Development

7.10 Shijiazhuang SIYAO

7.10.1 Shijiazhuang SIYAO Company Information

7.10.2 Shijiazhuang SIYAO Introduction and Business Overview

7.10.3 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.10.4 Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product Offerings

7.10.5 Shijiazhuang SIYAO Recent Development

7.11 Yiling Pharmaceutical

7.11.1 Yiling Pharmaceutical Company Information

7.11.2 Yiling Pharmaceutical Introduction and Business Overview

7.11.3 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales, Revenue and Gross Margin (2019-2024)

7.11.4 Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product Offerings

7.11.5 Yiling Pharmaceutical Recent Development

8 Industry Chain Analysis

8.1 Gliclazide Sustained-release Tablet Industrial Chain

8.2 Gliclazide Sustained-release Tablet Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Gliclazide Sustained-release Tablet Sales Model

8.5.2 Sales Channel

8.5.3 Gliclazide Sustained-release Tablet Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Servier Laboratories

Torrent Pharmaceuticals

Aurobindo Pharma

TEVA

Zydus Cadila Healthcare

Sanofi

Mylan Pharmaceuticals

Accord Healthcare

Yiling Pharmaceutical

Lukang Jituan Saite Yaoye

Shijiazhuang SIYAO

List of Tables

Table 1. Gliclazide Sustained-release Tablet Market Trends

Table 2. Gliclazide Sustained-release Tablet Market Drivers & Opportunity

Table 3. Gliclazide Sustained-release Tablet Market Challenges

Table 4. Gliclazide Sustained-release Tablet Market Restraints

Table 5. Global Gliclazide Sustained-release Tablet Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Gliclazide Sustained-release Tablet Revenue Market Share by Company (2019-2024)

Table 7. Global Gliclazide Sustained-release Tablet Sales Volume by Company (2019-2024) & (K Units)

Table 8. Global Gliclazide Sustained-release Tablet Sales Volume Market Share by Company (2019-2024)

Table 9. Global Market Gliclazide Sustained-release Tablet Price by Company (2019-2024) & (US$/Unit)

Table 10. Key Manufacturers Gliclazide Sustained-release Tablet Manufacturing Base Distribution and Headquarters

Table 11. Key Manufacturers Gliclazide Sustained-release Tablet Product Type

Table 12. Key Manufacturers Time to Begin Mass Production of Gliclazide Sustained-release Tablet

Table 13. Global Gliclazide Sustained-release Tablet Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gliclazide Sustained-release Tablet as of 2023)

Table 15. Mergers & Acquisitions, Expansion Plans

Table 16. Global Gliclazide Sustained-release Tablet Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 17. Global Gliclazide Sustained-release Tablet Sales Value by Type (2019-2024) & (US$ Million)

Table 18. Global Gliclazide Sustained-release Tablet Sales Value by Type (2025-2030) & (US$ Million)

Table 19. Global Gliclazide Sustained-release Tablet Sales Market Share in Value by Type (2019-2024) & (%)

Table 20. Global Gliclazide Sustained-release Tablet Sales Market Share in Value by Type (2025-2030) & (%)

Table 21. Global Gliclazide Sustained-release Tablet Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)

Table 22. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2019-2024) & (K Units)

Table 23. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2025-2030) & (K Units)

Table 24. Global Gliclazide Sustained-release Tablet Sales Market Share in Volume by Type (2019-2024) & (%)

Table 25. Global Gliclazide Sustained-release Tablet Sales Market Share in Volume by Type (2025-2030) & (%)

Table 26. Global Gliclazide Sustained-release Tablet Price by Type (2019-2024) & (US$/Unit)

Table 27. Global Gliclazide Sustained-release Tablet Price by Type (2025-2030) & (US$/Unit)

Table 28. Global Gliclazide Sustained-release Tablet Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 29. Global Gliclazide Sustained-release Tablet Sales Value by Application (2019-2024) & (US$ Million)

Table 30. Global Gliclazide Sustained-release Tablet Sales Value by Application (2025-2030) & (US$ Million)

Table 31. Global Gliclazide Sustained-release Tablet Sales Market Share in Value by Application (2019-2024) & (%)

Table 32. Global Gliclazide Sustained-release Tablet Sales Market Share in Value by Application (2025-2030) & (%)

Table 33. Global Gliclazide Sustained-release Tablet Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)

Table 34. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2019-2024) & (K Units)

Table 35. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2025-2030) & (K Units)

Table 36. Global Gliclazide Sustained-release Tablet Sales Market Share in Volume by Application (2019-2024) & (%)

Table 37. Global Gliclazide Sustained-release Tablet Sales Market Share in Volume by Application (2025-2030) & (%)

Table 38. Global Gliclazide Sustained-release Tablet Price by Application (2019-2024) & (US$/Unit)

Table 39. Global Gliclazide Sustained-release Tablet Price by Application (2025-2030) & (US$/Unit)

Table 40. Global Gliclazide Sustained-release Tablet Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Global Gliclazide Sustained-release Tablet Sales Value by Region (2019-2024) & (US$ Million)

Table 42. Global Gliclazide Sustained-release Tablet Sales Value by Region (2025-2030) & (US$ Million)

Table 43. Global Gliclazide Sustained-release Tablet Sales Value by Region (2019-2024) & (%)

Table 44. Global Gliclazide Sustained-release Tablet Sales Value by Region (2025-2030) & (%)

Table 45. Global Gliclazide Sustained-release Tablet Sales Volume by Region (K Units): 2019 VS 2023 VS 2030

Table 46. Global Gliclazide Sustained-release Tablet Sales Volume by Region (2019-2024) & (K Units)

Table 47. Global Gliclazide Sustained-release Tablet Sales Volume by Region (2025-2030) & (K Units)

Table 48. Global Gliclazide Sustained-release Tablet Sales Volume by Region (2019-2024) & (%)

Table 49. Global Gliclazide Sustained-release Tablet Sales Volume by Region (2025-2030) & (%)

Table 50. Global Gliclazide Sustained-release Tablet Average Price by Region (2019-2024) & (US$/Unit)

Table 51. Global Gliclazide Sustained-release Tablet Average Price by Region (2025-2030) & (US$/Unit)

Table 52. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 53. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value, (2019-2024) & (US$ Million)

Table 54. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value, (2025-2030) & (US$ Million)

Table 55. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Volume, (2019-2024) & (K Units)

Table 56. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Volume, (2025-2030) & (K Units)

Table 57. Servier Laboratories Company Information

Table 58. Servier Laboratories Introduction and Business Overview

Table 59. Servier Laboratories Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 60. Servier Laboratories Gliclazide Sustained-release Tablet Product Offerings

Table 61. Servier Laboratories Recent Development

Table 62. Torrent Pharmaceuticals Company Information

Table 63. Torrent Pharmaceuticals Introduction and Business Overview

Table 64. Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 65. Torrent Pharmaceuticals Gliclazide Sustained-release Tablet Product Offerings

Table 66. Torrent Pharmaceuticals Recent Development

Table 67. Aurobindo Pharma Company Information

Table 68. Aurobindo Pharma Introduction and Business Overview

Table 69. Aurobindo Pharma Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 70. Aurobindo Pharma Gliclazide Sustained-release Tablet Product Offerings

Table 71. Aurobindo Pharma Recent Development

Table 72. Teva Company Information

Table 73. Teva Introduction and Business Overview

Table 74. Teva Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 75. Teva Gliclazide Sustained-release Tablet Product Offerings

Table 76. Teva Recent Development

Table 77. Zydus Cadila Healthcare Company Information

Table 78. Zydus Cadila Healthcare Introduction and Business Overview

Table 79. Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 80. Zydus Cadila Healthcare Gliclazide Sustained-release Tablet Product Offerings

Table 81. Zydus Cadila Healthcare Recent Development

Table 82. Sanofi S.A. Company Information

Table 83. Sanofi S.A. Introduction and Business Overview

Table 84. Sanofi S.A. Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 85. Sanofi S.A. Gliclazide Sustained-release Tablet Product Offerings

Table 86. Sanofi S.A. Recent Development

Table 87. Mylan Pharmaceuticals Company Information

Table 88. Mylan Pharmaceuticals Introduction and Business Overview

Table 89. Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 90. Mylan Pharmaceuticals Gliclazide Sustained-release Tablet Product Offerings

Table 91. Mylan Pharmaceuticals Recent Development

Table 92. Accord Healthcare Company Information

Table 93. Accord Healthcare Introduction and Business Overview

Table 94. Accord Healthcare Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 95. Accord Healthcare Gliclazide Sustained-release Tablet Product Offerings

Table 96. Accord Healthcare Recent Development

Table 97. Lukang Jituan Saite Yaoye Company Information

Table 98. Lukang Jituan Saite Yaoye Introduction and Business Overview

Table 99. Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 100. Lukang Jituan Saite Yaoye Gliclazide Sustained-release Tablet Product Offerings

Table 101. Lukang Jituan Saite Yaoye Recent Development

Table 102. Shijiazhuang SIYAO Company Information

Table 103. Shijiazhuang SIYAO Introduction and Business Overview

Table 104. Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 105. Shijiazhuang SIYAO Gliclazide Sustained-release Tablet Product Offerings

Table 106. Shijiazhuang SIYAO Recent Development

Table 107. Yiling Pharmaceutical Company Information

Table 108. Yiling Pharmaceutical Introduction and Business Overview

Table 109. Yiling Pharmaceutical Gliclazide Sustained-release Tablet Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 110. Yiling Pharmaceutical Gliclazide Sustained-release Tablet Product Offerings

Table 111. Yiling Pharmaceutical Recent Development

Table 112. Key Raw Materials Lists

Table 113. Raw Materials Key Suppliers Lists

Table 114. Gliclazide Sustained-release Tablet Downstream Customers

Table 115. Gliclazide Sustained-release Tablet Distributors List

Table 116. Research Programs/Design for This Report

Table 117. Key Data Information from Secondary Sources

Table 118. Key Data Information from Primary Sources

List of Figures

Figure 1. Gliclazide Sustained-release Tablet Product Picture

Figure 2. Global Gliclazide Sustained-release Tablet Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 4. Global Gliclazide Sustained-release Tablet Sales Volume (2019-2030) & (K Units)

Figure 5. Global Gliclazide Sustained-release Tablet Sales Price (2019-2030) & (US$/Unit)

Figure 6. Gliclazide Sustained-release Tablet Report Years Considered

Figure 7. Global Gliclazide Sustained-release Tablet Players Revenue Ranking (2023) & (US$ Million)

Figure 8. Global Gliclazide Sustained-release Tablet Players Sales Volume Ranking (2023) & (K Units)

Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Gliclazide Sustained-release Tablet Revenue in 2023

Figure 10. Gliclazide Sustained-release Tablet Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 11. 30mg Picture

Figure 12. 60mg Picture

Figure 13. Other Picture

Figure 14. Global Gliclazide Sustained-release Tablet Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 15. Global Gliclazide Sustained-release Tablet Sales Value Market Share by Type, 2023 & 2030

Figure 16. Global Gliclazide Sustained-release Tablet Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)

Figure 17. Global Gliclazide Sustained-release Tablet Sales Volume Market Share by Type, 2023 & 2030

Figure 18. Global Gliclazide Sustained-release Tablet Price by Type (2019-2030) & (US$/Unit)

Figure 19. Product Picture of Hospital

Figure 20. Product Picture of Clinic

Figure 21. Product Picture of Other

Figure 22. Global Gliclazide Sustained-release Tablet Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 23. Global Gliclazide Sustained-release Tablet Sales Value Market Share by Application, 2023 & 2030

Figure 24. Global Gliclazide Sustained-release Tablet Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)

Figure 25. Global Gliclazide Sustained-release Tablet Sales Volume Market Share by Application, 2023 & 2030

Figure 26. Global Gliclazide Sustained-release Tablet Price by Application (2019-2030) & (US$/Unit)

Figure 27. North America Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 28. North America Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

Figure 29. Europe Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 30. Europe Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

Figure 31. Asia Pacific Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 32. Asia Pacific Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

Figure 33. South America Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 34. South America Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

Figure 35. Middle East & Africa Gliclazide Sustained-release Tablet Sales Value (2019-2030) & (US$ Million)

Figure 36. Middle East & Africa Gliclazide Sustained-release Tablet Sales Value by Country (%), 2023 VS 2030

Figure 37. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Value (%), (2019-2030)

Figure 38. Key Countries/Regions Gliclazide Sustained-release Tablet Sales Volume (%), (2019-2030)

Figure 39. United States Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 40. United States Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 41. United States Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 42. Europe Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 43. Europe Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 44. Europe Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 45. China Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 46. China Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 47. China Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 48. Japan Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 49. Japan Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 50. Japan Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 51. South Korea Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 52. South Korea Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 53. South Korea Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 54. Southeast Asia Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 55. Southeast Asia Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 56. Southeast Asia Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 57. India Gliclazide Sustained-release Tablet Sales Value, (2019-2030) & (US$ Million)

Figure 58. India Gliclazide Sustained-release Tablet Sales Value by Type (%), 2023 VS 2030

Figure 59. India Gliclazide Sustained-release Tablet Sales Value by Application (%), 2023 VS 2030

Figure 60. Gliclazide Sustained-release Tablet Industrial Chain

Figure 61. Gliclazide Sustained-release Tablet Manufacturing Cost Structure

Figure 62. Channels of Distribution (Direct Sales, and Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions